HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chaux, A. Articles by Gray, R. J. Search for Related Content PubMed PubMed Citation Articles by Chaux, A. Articles by Gray, R. J.

The Journal of Thoracic and Cardiovascular Surgery, Vol 88, 706-717, Copyright © 1984 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association

ARTICLES

The St. Jude Medical bileaflet valve prosthesis. A 5 year experience

A Chaux, LS Czer, JM Matloff, MA DeRobertis, ME Stewart, TM Bateman, RM Kass, ME Lee and RJ Gray

A 5 year experience with the bileaflet St. Jude Medical valve is reported. Between March, 1978, and June, 1982, 198 patients received 233 such valves (90 mitral, 73 aortic, and 35 double mitral-aortic valve replacements). Total follow-up was 4,896 patient-months; survivors were followed up for 1 to 5 years (mean 35 months). Early (30 day) mortality was 6.6% overall and 11.1% after mitral, 2.7% after aortic, and 2.9% after double valve replacement. Total late mortality was 15.2%; the actuarial survival rate at 4 years was 67% after mitral, 79% after aortic, and 79% after double valve replacement. Ischemic mitral valve disease was associated with an early mortality of 26.7% and a 4 year survival rate of 34%; without this high-risk subset, early mortality was 3.3% and the 4 year survival rate was 77% after mitral valve replacement. A multivariate logistic regression model identified three preoperative patient characteristics associated with increased postoperative mortality: ischemic mitral valve disease (p less than 0.001), a depressed left ventricular ejection fraction (less than 55%; p less than 0.05), and advanced New York Heart Association class (IV; p less than 0.05). Valve-related complications occurred in 14 patients (3.4% per patient-year). There were no instances of primary structural failure or hemolysis. Thromboembolism (nine patients, 2.2% per patient- year) occurred more frequently after double (3.7% per patient-year) or mitral valve replacement (2.3% per patient-year) than after aortic valve replacement (1.3% per patient-year) and more frequently in 12 patients receiving aspirin and dipyridamole (6.5% per patient-year) than in 173 patients receiving warfarin (1.9% per patient-year). No thromboembolic event was fatal. Reoperation was necessary because of one valve thrombosis, one valve erosion, and two perivalvular leaks due to endocarditis; three of the four patients survived reoperation (one valve-related death, 0.5%). Of 154 patients alive at latest follow-up, 85% were in New York Heart Association Class I or II, and 90% had improved by at least one class. This intermediate experience with the St. Jude Medical valve indicates that, in addition to its previously demonstrated excellent hemodynamic performance, there have been no instances of primary structural failure or hemolysis. Warfarin anticoagulation is recommended in all patients.

This article has been cited by other articles:

				P. Zhu and S. S. Feng Fifteen-Year Experience With Shanghai Disc Valve Prosthesis Asian Cardiovasc Thorac Ann, September 1, 2001; 9(3): 182 - 186. [Abstract] [Full Text] [PDF]

				J. F. Nistal, A. Hurle, J. M. Revuelta, and M. Gandarillas CLINICAL EXPERIENCE WITH THE CARBOMEDICS VALVE: EARLY RESULTS WITH A NEW BILEAFLET MECHANICAL PROSTHESIS J. Thorac. Cardiovasc. Surg., July 1, 1996; 112(1): 59 - 68. [Abstract] [Full Text]

				O. Jegaden, A. Eker, F. Delahaye, P. Montagna, J. Ossette, G. D. De Gevigney, and P. H. Mikaeloff Thromboembolic risk and late survival after mitral valve replacement with the St. Jude Medical valve Ann. Thorac. Surg., December 1, 1994; 58(6): 1721 - 1727. [Abstract] [PDF]

				S. Aoyagi, A. Oryoji, Y. Nishi, K. Tanaka, K. Kosuga, and K. Oishi Long-term results of valve replacement with the St. Jude Medical valve J. Thorac. Cardiovasc. Surg., December 1, 1994; 108(6): 1021 - 1029. [Abstract] [Full Text]

				V. J. DiSesa, J. J. Collins Jr, and L. H. Cohn Hematological complications with the St. Jude valve and reduced-dose Coumadin Ann. Thorac. Surg., August 1, 1989; 48(2): 280 - 283. [Abstract] [PDF]

				Y. Okita, S. Miki, K. Kusuhara, Y. Ueda, T. Tahata, Y. Tsukamoto, K. Yamanaka, and S. Shiraishi Intractable Hemolysis Caused by Perivalvular Leakage Following Mitral Valve Replacement with St. Jude Medical Prosthesis Ann. Thorac. Surg., July 1, 1988; 46(1): 89 - 92. [Abstract] [PDF]

				L. H. Edmunds Jr. Thrombotic and Bleeding Complications of Prosthetic Heart Valves Ann. Thorac. Surg., October 1, 1987; 44(4): 430 - 445. [Abstract] [PDF]

				J. B. Wong, R. K. Webb, and S. G. Pauker Double Trouble: A Patient with Two Prosthetic Values and Two Episodes of Intracranial Bleeding Med Decis Making, August 1, 1987; 7(3): 174 - 193. [PDF]

				A. Damle, J. Coles, J. Teijeira, C. Pelletier, and J. Callaghan A Six-Year Study of the Omniscience Valve in Four Canadian Centers Ann. Thorac. Surg., May 1, 1987; 43(5): 513 - 521. [Abstract] [PDF]

				L. B. McGrath, L. Gonzalez-Lavin, W. J. Eldredge, M. Colombi, and D. Restrepo Thromboembolic and Other Events Following Valve Replacement in a Pediatric Population Treated with Antiplatelet Agents Ann. Thorac. Surg., March 1, 1987; 43(3): 285 - 287. [Abstract] [PDF]

				J. M. Duncan, D. A. Cooley, G. J. Reul, D. A. Ott, G. L. Hallman, O. H. Frazier, J. J. Livesay, W. E. Walker, and P. R. Adams Durability and Low Thrombogenicity of the St. Jude Medical Valve at 5-Year Follow-up Ann. Thorac. Surg., November 1, 1986; 42(5): 500 - 505. [Abstract] [PDF]